Promoting Longevity: A Global Approach

    May 2017 in “ Maturitas ”
    Esperanza Navarro Pardo, Patricia Villacampa, Antonio Cano
    Image of study
    TLDR The document concludes that managing health issues like menopause, cardiovascular risk, and hair loss is crucial for promoting longevity in aging women.
    The document from 2017 discussed health issues in aging women, focusing on menopause, cardiovascular risk, and hair loss. It emphasized the need for proper preparation before oocyte donation, managing estrogen and insulin levels, and addressing thrombophilia. It noted an increase in arthritis during perimenopause and suggested a potential link between estrogen and post-menopausal cognitive health, although evidence was not definitive. The importance of physical activity and ICT technologies for healthy aging was highlighted. A study found that women with premature ovarian insufficiency (POI) had worse cardiovascular risk profiles compared to premenopausal controls but did not show increased subclinical atherosclerosis. The document also covered hair loss in midlife women, including androgenetic alopecia and telogen effluvium, and the importance of accurate diagnosis and treatments like minoxidil.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Why balding gets worse in every generation?

      in Chat  81 upvotes 6 months ago
      Balding seems to worsen with each generation, possibly due to stress, diet, and environmental factors. The user started treatments like Minoxidil and finasteride.

      community FINASTRIDE and switch to DUTASTRIDE, my experience

      in Progress Pictures  138 upvotes 3 months ago
      The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.

      community C’est terrible - at my wits end

      in Female  449 upvotes 1 year ago
      A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Similar Research

    5 / 1000+ results
      Hair Growth: Focus on Herbal Therapeutic Agents

      research Hair Growth: Focus on Herbal Therapeutic Agents

      41 citations, July 2015 in “Current Drug Discovery Technologies”
      Some plants may help with hair growth and have fewer side effects than synthetic drugs, but more research is needed to confirm their effectiveness.
      Telogen Effluvium: A Common Form of Hair Loss

      research Telogen Effluvium: A Common Form of Hair Loss

      July 2018 in “Elsevier eBooks”
      Telogen Effluvium is a common, usually reversible hair loss condition, often improved by removing the trigger and possibly treated with various products, though their effectiveness is uncertain.
      Biology of the Hair Follicle: The Basics

      research Biology of the Hair Follicle: The Basics

      224 citations, March 2006 in “Seminars in Cutaneous Medicine and Surgery”
      The document concludes that understanding hair follicle biology can lead to better hair loss treatments.